×
Bavarian Nordic Share Holder Equity 2016-2024 | BVNRY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Bavarian Nordic share holder equity from 2016 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
View More
Bavarian Nordic Share Holder Equity 2016-2024 | BVNRY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Bavarian Nordic share holder equity from 2016 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$146.3B
Gilead Sciences (GILD)
$114.5B
Bristol Myers Squibb (BMY)
$114.2B
Vertex Pharmaceuticals (VRTX)
$108.7B
CSL (CSLLY)
$83.4B
Regeneron Pharmaceuticals (REGN)
$74.9B
GSK (GSK)
$69.3B
Argenex SE (ARGX)
$38.7B
Alnylam Pharmaceuticals (ALNY)
$31.8B
BioNTech SE (BNTX)
$26.8B
Illumina (ILMN)
$21.7B
BeiGene (ONC)
$20.5B
Biogen (BIIB)
$20.5B
Incyte (INCY)
$13.9B
Genmab (GMAB)
$13.8B
Genmab (GNMSF)
$13.7B
Intra-Cellular Therapies (ITCI)
$13.4B
Moderna (MRNA)
$13.1B
Insmed (INSM)
$13B
Bio-Techne Corp (TECH)
$12B
BioMarin Pharmaceutical (BMRN)
$11.7B
Sarepta Therapeutics (SRPT)
$11.3B
Vaxcyte (PCVX)
$10.6B
QIAGEN (QGEN)
$10.5B
Exelixis (EXEL)
$10.3B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Exact Sciences (EXAS)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.5B
Repligen (RGEN)
$9B
Roivant Sciences (ROIV)
$8.1B